Omeros Corporation (NASDAQ:OMER) developer of small-molecule and protein therapeutics, is expected to report third quarter earnings results, after market close, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.61 per share from revenue of $ 19.11 million.
Looking ahead, the full year loss are expected at $ 2.19 per share on the revenues of $ 70.31 million.
Previous Quarter Performance
Omeros Corporation reported loss for the second quarter of $ 0.61 per share, from the revenue of $ 13.53 million. Street analysts expected Omeros Corporation to report loss of $ 0.64 per share on revenue of $ 14.65 million for the second quarter. The bottom line results beat street analysts by $ 0.03 or 4.69 percent, at the same time, top line results fell short of analysts by $ 1.12 million or 7.65 percent.
Stock Performance
On Friday, shares of Omeros Corporation has traded high as $ 10.84 and has cracked $ 10.38 on the downward trend, reaching $ 10.44 with volume of 413.90 thousand shares.
According to the previous trading day, closing price of $ 10.44, representing a 27.53 % increase from the 52 week low of $ 8.50 and a 57.42 % decrease over the 52 week high of $ 25.46.
The company has a market capital of $ 641.21 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Omeros Corporation will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.omeros.com
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The companys clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases.
